



Transgene Announces its Financial Calendar for 2013

Strasbourg, January 16, 2013 - Transgene SA (Euronext Paris: FR0005175080) today announces the following financial reporting dates for 2013:

March 22, 2013: 2012 Annual Results and Strategic Update

April 22, 2013 Q1 Financial Report

June 19, 2013: Annual Shareholders' Meeting

September 12, 2013: Half-Year Financial Report

October 21, 2013: Q3 Financial Report

About Transgene:

Transgene, a member of the Institut Mérieux Group, is a publicly traded French biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. Transgene has four compounds in phase 2 clinical development: TG4010 and JX594/TG6006 having already completed initial phase 2 trials, TG4001 and TG4040. Transgene has concluded strategic agreements for the development of two of its immunotherapy products: an option agreement with Novartis for the development of TG4010 to treat various cancers and an in-licensing agreement with US-based Jennerex, Inc. to develop and market JX594/TG6006, an oncolytic virus. Transgene has bio-manufacturing capacities for viral-based products. Additional information about Transgene is available at www.transgene.fr.

Contacts:

Transgene

Stéphane Boissel, Executive Vice President & CFO, +33 (0)3 88 27 91 02

Elisabetta Castelli, Director IR, +33 (0)3 88 27 91 21

MC Services

Raimund Gabriel, +49 89 210 228 30

Shaun Brown, +44 207 148 5998